<DOC>
	<DOCNO>NCT00720499</DOCNO>
	<brief_summary>The primary objective study determine optimum dose ( ) BI 1744 CL administer 5 microgram tiotropium bromide solution inhalation , deliver RespimatÂ® inhaler , daily four week patient chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Efficacy Safety 4 Weeks Treatment With Orally Inhaled BI1744/Tiotropium Bromide Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>1 . All patient must sign informed consent consistent ICHGCP guideline prior participation trial , include medication washout restriction 2 . All patient must diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients must relatively stable airway obstruction postbronchodilator FEV1 &gt; = 30 % predict normal &lt; 80 % predict normal postbronchodilator FEV1 / FVC &lt; 70 % Visit 1 3 . Male female patient , 40 year age old 4 . Patients must current exsmokers smoke history 10 pack year 5 . Patients must able perform technically acceptable pulmonary function test PEF measurement , must able maintain record ( Patient Daily eDiary ) study period require protocol 6 . Patients must able inhale medication competent manner Respimat inhaler meter dose inhaler ( MDI ) . 7. additional inclusion criterion apply . 1 . Patients significant disease COPD 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis ; 3 . Patients history asthma total blood eosinophil count &gt; = 600/mm3 . 4 . Patients follow condition : diagnosis thyrotoxicosis , diagnosis paroxysmal tachycardia ( &gt; 100 beat per minute ) , mark baseline prolongation QT/QTc interval ( e.g . repeat demonstration QTcF* interval &gt; 450 m ) , history additional risk factor Torsade de Pointes ( TdP ) ( e.g . heart failure , hypokalemia , family history Long QT Syndrome ) 5 . Patients follow condition : history myocardial infarction within 1 year screen visit ( Visit 1 ) , diagnosis clinically relevant cardiac arrhythmia , know active tuberculosis , malignancy patient undergone resection , radiation therapy chemotherapy within last five year , history lifethreatening pulmonary obstruction , history cystic fibrosis , clinically evident bronchiectasis , history significant alcohol drug abuse 6 . Patients undergone thoracotomy pulmonary resection 7 . Patients regularly use daytime oxygen therapy one hour per day investigator 's opinion unable abstain use oxygen therapy clinic visit . 8 . Pregnant nursing woman 9 . Women childbearing potential use two effective method birth control ( one barrier one nonbarrier ) . Female patient consider childbearing potential unless surgically sterilise hysterectomy bilateral tubal ligation , postmenopausal least two year 10 . Patients previously randomize study currently participate another study 11 . Patients unable comply pulmonary medication restriction prior randomization 12 . Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit 13. additional exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>